UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/588,679	8,679 05/29/2007 Gavril W. Pasternak		62078(51590)	5097
	7590 12/10/200 NGELL PALMER & D	EXAMINER		
P.O. BOX 5587		LANDSMAN, ROBERT S		
BOSTON, MA	02203		ART UNIT	PAPER NUMBER
			1647	
			MAIL DATE	DELIVERY MODE
			12/10/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary		Application	on No.	Applicant(s)		
		10/588,67	79	PASTERNAK ET AL.		
		Examiner	•	Art Unit		
		ROBERT	LANDSMAN	1647		
The MA Period for Reply	ILING DATE of this communicat	ion appears on the	e cover sheet with the	correspondence a	ddress	
A SHORTENE WHICHEVER - Extensions of time after SIX (6) MON - If NO period for re - Failure to reply wil Any reply received	D STATUTORY PERIOD FOR S LONGER, FROM THE MAIL may be available under the provisions of 37 THS from the mailing date of this communically is specified above, the maximum statutor hin the set or extended period for reply will, I by the Office later than three months after the adjustment. See 37 CFR 1.704(b).	ING DATE OF TH 7 CFR 1.136(a). In no evation. Try period will apply and weby statute, cause the app	HIS COMMUNICATIO ent, however, may a reply be ti ill expire SIX (6) MONTHS fror lication to become ABANDON	N. imely filed in the mailing date of this of ED (35 U.S.C. § 133).	·	
Status						
2a)⊠ This action 3)□ Since thi	ive to communication(s) filed o on is FINAL . 2b)[s application is in condition for a accordance with the practice u	☐ This action is nallowance except	on-final. for formal matters, pr		e merits is	
Disposition of Cla	nims					
4a) Of the 5)⊠ Claim(s) 6)⊠ Claim(s) 7)□ Claim(s)	1-16 and 18-21 is/are pending above claim(s) 21 is/are without 1-6 and 8-13 is/are allowed. 7-14 and 19 is/are rejected. 18 and 20 is/are objected to. are subject to restriction	drawn from consic	leration.			
Application Pape	rs					
10)☐ The draw Applicant Replacen	ification is objected to by the Exing(s) filed on is/are: a) may not request that any objection ent drawing sheet(s) including the or declaration is objected to by	accepted or b) n to the drawing(s) be correction is requir	ne held in abeyance. See dif the drawing(s) is of	ee 37 CFR 1.85(a). ojected to. See 37 C		
Priority under 35	U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
	erson's Patent Drawing Review (PTO-osure Statement(s) (PTO/SB/08)	948)	4) Interview Summar Paper No(s)/Mail E 5) Notice of Informal 6) Other:	Oate		

Application/Control Number: 10/588,679 Page 2

Art Unit: 1647

DETAILED ACTION

A phone call was placed to Dr. Hunter-Ensor on December 1, 2008 to discuss minor issues.

However, Dr. Hunter was unable to be reached. Therefore, an Office Action with the following issues is

being mailed to Applicants.

1. Formal Matters

A. The Amendment filed 10/27/08 has been entered into the record.

B. Claims 1-16 and 18-21 are pending. Claim 21 is withdrawn as being drawn to a non-elected

invention. Claim 20, which is not withdrawn as seen by the status identifier (i.e. Original) is being

withdrawn by the Examiner since it depends from withdrawn claim 21. Therefore, claims 1-16, 18 and 19

are the subject of this Office Action.

2. Specification

A. The objection to the specification has been overcome in view of Applicants' submission of a new

Figure 1A. However, it is noted that this new Figure is labeled "(Sheet 1 of 26)" whereas no other Figures

are labeled as such.

3. Claim Objections

A. All claim objections have been withdrawn in view of Applicants' amendments.

B. Claim 18 is objected to since it depends from canceled claim 17.

4. Claim Rejections - 35 USC § 112, first paragraph - scope of enablement

A. The rejection of claims 14-20 under 35 USC 112, first paragraph, has been withdrawn in view of

Applicants' amendments to the claims.

Application/Control Number: 10/588,679 Page 3

Art Unit: 1647

5. Claim Rejections - 35 USC § 112, second paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the

subject matter which the applicant regards as his invention.

.A. All rejections under 35 USC 112, second paragraph, have been withdrawn in view of Applicants'

amendments to the claims.

B. Claim 7 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to

particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 7 is confusing, though the Examiner is open to arguments from Applicants. The claim

recites a polypeptide selected from the group consisting of SEQ ID NO:51, 53, 55, 57, 59 and 61.

However, it then states that the polypeptide is a heterodimer. It is believed that the heterodimer must

consist of at least two polypeptides of SEQ ID NO:51, 53, 55, 57, 59 and 61. However, it is not clear if

Applicants intend for the claim to cover other polypeptides, in which the recited group does not "consist,"

or if the heterodimer consists of two or more polypeptides selected from SEQ ID NO:51, 53, 55, 57, 59

and 61. Furthermore "a polypeptide" is singular. Therefore, it is also unclear how the polypeptide could

be a homodimers or heterodimer which both comprise a plurality of polypeptides.

The claim could be amended to, for example, "A homodimers or heterodimer consisting of two or

more polypeptides selected from the group consisting of SEQ ID NO:51, 53, 55, 57, 59 and 61" if this is

what Applicants intend.

C. Claims 14-16 and 19 are confusing since it appears that the same cell is being contacted with both

a composition and an opioid. Most assays use two populations of cells to measure two different

compounds/events. In other words, one population of cells would be contacted with a test compound and

a second population of cells would be contacted with an opioid and both populations compared to a

control. Respectfully, when most assays are performed the cells are destroyed or otherwise unusable so

the use of another ligand/compound would be expected to be effective. The claims, as written may, in

fact, be what Applicants intend. The Examiner only asks clarification.

6. Conclusion

Application/Control Number: 10/588,679 Page 4

Art Unit: 1647

A. Claims 1-6 and 8-13 are allowable.

B. Non-elected claim 21 and its dependent claim 20 would need to be canceled upon allowance of the elected claims. Claims 20 and 21 may be rejoined under *In re Ochiai* if they meet all of the criteria for patentability including the requirements of 35 USC 101, 102, 103 and 112.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Advisory information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Landsman, Ph.D. whose telephone number is (571) 272-0888. The examiner can normally be reached on M-F 10 AM – 6:30 PM (eastern).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath Rao can be reached on 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Robert Landsman/ Primary Examiner, Art Unit 1647